The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2019 | Immunotherapeutic approaches to myeloma
David Avigan, MD, Harvard Medical School, Boston, MA, gives an update on the immunotherapeutic approaches to multiple myeloma (MM) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA. The most recent efficacy data on the use of CAR T-cells targetting BCMA for MM is discussed as is the use of bispecific antibodies, bispecific T-cell engagers (BiTEs), antibody-drug conjugates and vaccine therapies.
